Sandoz

Sandoz is now a member of the Business Council for the UN, a program of the United Nations Foundation, that nurtures cross-sector collaboration and facilitates corporate engagement at the #UN and on the Sustainable Development Goals. We look forward to the opportunities this collaboration will bring to create impact at scale on our shared goals, including driving #Sustainability and #PioneeringAccess for a healthier world. BCUN, United Nations Foundation

Sandoz today reported its net sales results for the third quarter (Q3) and first nine months (9M) of 2024. The company also raised its full-year sales guidance, based on performance year-to-date. Q3 net sales were USD 2.6 billion, an increase of 12% in constant currencies (cc) compared to the prior year quarter. 9M net sales were USD 7.6 billion, an increase of 9% in cc. Growth was led by the biosimilars business (+37% in Q3, +32% for the year to date), driven by new products and the base portfolio, while the generics business saw a pick-up in Q3, backed by solid demand (+4%, versus +2% for the 9M period). All three regions saw continued growth, with Europe up 12% in Q3 (9M: +6%), North America +18% in the quarter (9M: +15%) and International +8% for Q3 (9M: +9%). On the back of this strong momentum in its biosimilars business and solid generics demand, Sandoz has increased its full-year 2024 net sales guidance to high-single digit growth in cc versus prior year (from mid- to high-single digit) and confirmed its core EBITDA margin guidance of around 20%.  For further details, see the Sandoz financial results media release: https://lnkd.in/e-PsrUBf

On November 8 at 11:00 CET, Sandoz and the Slovenian Ministrstvo za gospodarstvo, turizem in šport / Ministry of the Economy, Tourism and Sport has invited a panel of public health and policy experts to discuss the importance of a stronger European biomanufacturing footprint. Join us to learn more about why and how we must optimize the EU landscape to meet the growing demand for medicines by enabling access to high quality, more affordable biologics for patients. Register to attend this discussion live at:   https://lnkd.in/ehkQFK-U Thank you in advance to our panel of experts for participating in the discussion. #Biomanufacturing #Biosimilars 

Our CEO Richard Saynor shares his perspective on the need for policy changes to help reduce healthcare costs and ensure patient access to critical medicines.    Read more in Richard’s article 👇 #Sandoz

Triple honors for Sandoz at last night’s Global Generics & Biosimilars Awards in Milan, where we won the night’s top award, Company of the Year, CEO Richard Saynor was named as Leader of the Year, and Sandoz also took the Biosimilars Initiative of the Year Award. Congratulations to Richard (who has now won this award for four of the past five years), to the biosimilars team behind our recent string of successful launches and approvals, and – most of all – to the 20,000-plus employees who all deserve individual medallions for the company award! The wins are testament to our common Purpose – pioneering access for patients – and we accept them in that spirit. Our congratulations to the other winners and our thanks to the Generics Bulletin team, who do a great job day in day out of pioneering access to essential news about our system-critical industry! See here for more details: https://lnkd.in/gj8Gm2wU Now it’s back to work! #GGBA #Biosimilars #Generics

Today, on #WorldSightDay, we recognize the millions of people worldwide who are impacted by blindness and vision impairment. There are many challenges stemming from vision loss and accessible treatment options are crucial to help patients maintain their sight and improve their quality of life. Join the #LoveYourEyes campaign along with advocates from around the world committed to prioritizing eye health including the International Agency for the Prevention of Blindness (IAPB). Learn more about the day here: https://lnkd.in/eNGA4Dz3 #Ophthalmology

At Sandoz, the wellbeing of our employees is critical, and a natural extension of our Purpose. This is why we have introduced support for our associates ranging from mindfulness to one-to-one counselling. Learn more: https://lnkd.in/gBpsA4Nf #Careers #SandozLife #WorldMentalHealthDay

Exactly one year ago, Sandoz celebrated becoming the ‘oldest’ new company listed on the SIX Swiss Exchange. The spin-off from our parent company marked the start of a new era for Sandoz, a brand that dates back to 1886. A lot has happened since we rang that initial cowbell 12 months ago (the traditional ‘entry ceremony’ for new joiners at the SIX in Zurich). Sandoz today has clearly established itself as the independent global leader in off-patent medicines, with steady sales growth backed up by a string of strategic achievements, from key acquisitions to product approvals and launches. Most importantly, we are investing significantly to drive future growth, both in the rapidly-accelerating biosimilar segment and in key areas of our core generics business. We have a broad and deep pipeline including an industry-leading 25 biosimilars and more than 450 generics. If you've taken one of our medicines in the last year, you're in good company: our medicines provide more than 800 million treatments every year. So thank you for your trust in Sandoz. Together, we'll continue to push the boundaries of what's possible in healthcare! #PioneeringAccess

Unsustainable pricing pressure and abusive patent litigation tactics are just a few factors that can cause market exits which contribute to drug shortages. For over 40 years, generic medicines have improved access for US patients, transforming health outcomes and driving down out-of-pocket costs for millions, but now urgent action is needed to be sure all patients can get the medicines they need, when they need them. Our goal is to ensure uninterrupted access to affordable medicines and make a difference for patients and the US healthcare system – but we cannot do it alone. Sandoz and the Association for Accessible Medicines urge the government to consider the unique aspects that differentiate the brand and generic business models and adopt policies that will reduce drug shortages by improving the long-term sustainability of the generic drug market. What happens next must happen now. Learn more about what Sandoz is doing at www.us.sandoz.com #PioneeringAccess

The passing of the Hatch-Waxman Act in 1984 helped the promise of generic medicines become a reality in the US. Now, forty years later, we sit on the brink of realizing the immense potential of biosimilars to reduce costs and increase access to high-priced biologic treatments in the US. It’s a pivotal moment – and one that is not without its challenges, including misaligned incentives across the US healthcare system that can inflate healthcare costs and restrict patient access to these more affordable alternatives. It’s crucial for stakeholders to advocate for policy changes that promote fair competition and prioritize patient welfare. It is only then that the full potential of biosimilars will be unlocked, ensuring a more sustainable and equitable healthcare system. What happens next must happen now. Learn more about what Sandoz is doing at www.us.sandoz.com #PioneeringAccess